Image

    Deuruxolitinib for Alopecia Areata

    January 2026 in “ PubMed
    Alexander J. Robbins, Mariana Phillips
    Studysummary This review discusses the approval of deuruxolitinib, an oral JAK inhibitor, by the FDA in July 2024 for treating severe alopecia areata in adults, highlighting its role as the third approved oral treatment option alongside baricitinib and ritlecitinib.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on pubmed.ncbi.nlm.nih.gov →
    Discuss this study in the Community →